MedTrace Logo

Actigraphic Analysis of Treatment Response

NCT00723580 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-08-18

Study results available
· View outcomes & findings →

Summary

The study examines and illustrates the utility of utilizing actigraphic measurements to assess treatment response.

Conditions

  • Sleep Disorders, Circadian Rhythm
  • Insomnia
  • Psychomotor Agitation

Interventions

DRUG

risperidone

Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).

Sponsors & Collaborators

  • Child Psychopharmacology Institute

    lead OTHER

Principal Investigators

  • Bill J Duke, M.A., Ph.D. · Child Psychopharmacology Institute

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
10 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723580 on ClinicalTrials.gov